Notice of Intent for commercial items

This is a combined synopsis/solicitation Notice of Intent for commercial items prepared in accordance with the format in FAR Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotations are being requested, and a written solicitation will not be issued. The solicitation number for this acquisition is NIAID NOI 12117 issued as a Notice of Intent. The incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2005-58, dated May 18, 2012. The associated North American Industry Classification System (NAICS) Code is 541711 which has a business size standard of 500. This acquisition will be processed under Simplified Acquisition Procedures (SAP) and is a small business set-aside. Small, small disadvantage, minority, veteran owned, 8a and HUD zone companies, etc are encouraged to submit quotations. All responsible sources may submit offers that will be considered by this agency. The National Institutes of Health, National Institute of Allergy and Infectious Diseases intends to award on a sole source basis to Oxford Biomedical Research for the following reagents in order to maintain the integrity of the experiments being done in the lab (Item/description/Qty): 1) PGE2 Monoclonal EIA Kit (Qty-20); 2) Lipoxin A4 EIA Kit (Qty-20); 3) PGF2alpha EIA Kit (Qty-20); 4) PGF2alpha EIA Kit (Qty-20); 5) PGF2alpha EIA Kit (Qty-20); 6) Leukotriene C4 EIA Kit (Qty-20); 7) 15-Epi-Lipoxin A4 EIA Kit (Qty-20). Reagents from Oxford Biomedical Research were used extensively in work for the paper that was published; Chen et al. JEM 2008. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. The following factors shall be used to evaluate offers: 1) technical capability to meet required specifications and 2) price 3) Delivery. Place of delivery NIH/NIAID Bethesda, MD 20892 . The government will award a fixed price purchase order to the responsible contractor. The FOB point shall be Bethesda, MD The following Federal Acquisition Regulations provisions and clauses apply to the acquisition: FAR 52.212-1, Instructions to Offerors - Commercial Items; FAR 52.212-2, Evaluation - Commercial Items; Far 52.212-3, Offeror Representation and Certifications - Commercial Items; Far 52.212-4, Contract Terms and Conditions -Commercial Items; FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items; and FAR 52.232-33, Payment by Electronic Funds Transfer-Central Contractor Registration (Oct 2003). In order to be considered for an award, an offeror must have completed the electronic Online Representations and Certifications Application (ORCA) at https://orca.bpn.gov in accordance with FAR 4.1201(a). By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the CCR at www.ccr.gov prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation. [Note: Lack of registration in the Central Contractor Registration will make an offeror ineligible for award]. Copies of the aforementioned clauses are available upon request by telephone to Daniel Herdman at (301) 402-2607. All responsible sources may submit offers that will be considered by this agency. Offers must be submitted no later than 4:00 p.m. Eastern Time (ET), close date 07/16/2012. Delivery address through the U.S. Postal Service, NIH/NIAID/AMOB, 10401 Fernwood Road, Room 2NE52c, Bethesda, MD, 20817-4811. Electronic and fax quotations are not accepted. Requests for information concerning this requirement are to be addressed to Daniel Herdman at (301) 301-402-2607 or herdmand@mail.nih.gov. It is the vendor's responsibility to confirm receipt of all quotations and/or questions by the closing date of this announcement. Collect calls will not be accepted.